IRMD · IRadimed Corporation

IRadimed reported a strong first quarter for 2026, with revenue of $22.0 million, up 13% year-over-year, driven by growth in MRI-compatible IV infusion pump systems ($7.7M vs $6.0M) and patient vital signs monitoring systems ($7.1M vs $6.5M). Gross margin improved to 77% from 76%. Operating income rose 33% to $7.2 million, and net income increased 24% to $5.8 million, yielding record GAAP diluted EPS of $0.45 (up 22%). Non-GAAP diluted EPS was $0.49, up 17%. The company declared a quarterly dividend of $0.20 per share, payable May 29, 2026. Management highlighted the commercial launch of the next-generation 3870 MRI-compatible IV infusion pump system, with strong early orders exceeding prior-generation levels. Significant shipments are expected to begin in Q2, with full impact in Q3. For Q2 2026, guidance calls for revenue of $20-21 million, GAAP EPS of $0.40-0.44, and non-GAAP EPS of $0.44-0.48. Full-year 2026 guidance was reaffirmed: revenue $91-96 million, GAAP EPS $1.90-2.05, non-GAAP EPS $2.06-2.21. Operating cash flow improved to $8.3 million from $4.3 million in the prior year.